Five Prime Therapeutics Inc (NASDAQ:FPRX) insider Value Fund L. P. Biotechnology purchased 601,482 shares of the firm’s stock in a transaction dated Tuesday, October 8th. The stock was acquired at an average cost of $3.74 per share, for a total transaction of $2,249,542.68.
Shares of Five Prime Therapeutics stock traded up $0.68 during trading hours on Wednesday, hitting $4.38. The company’s stock had a trading volume of 265,875 shares, compared to its average volume of 373,322. Five Prime Therapeutics Inc has a twelve month low of $3.22 and a twelve month high of $14.48. The firm has a fifty day moving average of $5.11 and a 200-day moving average of $7.66. The stock has a market cap of $135.72 million, a price-to-earnings ratio of -1.06 and a beta of 2.57. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.87 and a current ratio of 6.87.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.09). Five Prime Therapeutics had a negative net margin of 842.84% and a negative return on equity of 62.13%. The business had revenue of $3.33 million during the quarter, compared to analyst estimates of $5.53 million. On average, sell-side analysts expect that Five Prime Therapeutics Inc will post -3.91 earnings per share for the current fiscal year.
Several equities analysts have recently commented on the company. Zacks Investment Research raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 6th. ValuEngine raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Guggenheim lowered Five Prime Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, September 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. Five Prime Therapeutics currently has an average rating of “Hold” and an average price target of $14.40.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Read More: What is Put Option Volume?
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.